These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 22476979)
1. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Ijichi N; Shigekawa T; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S Horm Cancer; 2012 Aug; 3(4):147-59. PubMed ID: 22476979 [TBL] [Abstract][Full Text] [Related]
2. FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Shigekawa T; Ijichi N; Ikeda K; Horie-Inoue K; Shimizu C; Saji S; Aogi K; Tsuda H; Osaki A; Saeki T; Inoue S Horm Cancer; 2011 Oct; 2(5):286-97. PubMed ID: 21901488 [TBL] [Abstract][Full Text] [Related]
3. FOXP1 and estrogen signaling in breast cancer. Ijichi N; Ikeda K; Horie-Inoue K; Inoue S Vitam Horm; 2013; 93():203-12. PubMed ID: 23810008 [TBL] [Abstract][Full Text] [Related]
4. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808 [TBL] [Abstract][Full Text] [Related]
5. Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet. McCune K; Bhat-Nakshatri P; Thorat MA; Nephew KP; Badve S; Nakshatri H Cancer Res; 2010 Jan; 70(2):685-96. PubMed ID: 20068169 [TBL] [Abstract][Full Text] [Related]
6. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas. Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147 [TBL] [Abstract][Full Text] [Related]
7. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684 [TBL] [Abstract][Full Text] [Related]
8. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Bates GJ; Fox SB; Han C; Launchbury R; Leek RD; Harris AL; Banham AH Breast Cancer Res Treat; 2008 Oct; 111(3):453-9. PubMed ID: 18026833 [TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. Yamaguchi N; Nakayama Y; Yamaguchi N J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510 [TBL] [Abstract][Full Text] [Related]
10. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862 [TBL] [Abstract][Full Text] [Related]
11. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031 [TBL] [Abstract][Full Text] [Related]
12. Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells. Abe Y; Ijichi N; Ikeda K; Kayano H; Horie-Inoue K; Takeda S; Inoue S Cancer Sci; 2012 Apr; 103(4):806-12. PubMed ID: 22313737 [TBL] [Abstract][Full Text] [Related]
13. Metformin Prevents Tumor Cell Growth and Invasion of Human Hormone Receptor-Positive Breast Cancer (HR+ BC) Cells via Song C; Jung D; Kendi AT; Rho JK; Kim EJ; Horn I; Curran GL; Ghattamaneni S; Shim JY; Kang PS; Kang D; Thakkar JB; Dewan S; Lowe VJ; Lee SB Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000600 [TBL] [Abstract][Full Text] [Related]
14. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662 [TBL] [Abstract][Full Text] [Related]
15. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. Ademuyiwa FO; Thorat MA; Jain RK; Nakshatri H; Badve S Mod Pathol; 2010 Feb; 23(2):270-5. PubMed ID: 19946260 [TBL] [Abstract][Full Text] [Related]
16. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556 [TBL] [Abstract][Full Text] [Related]
17. More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response. Fu X; Huang C; Schiff R Breast Cancer Res; 2011 Apr; 13(2):307. PubMed ID: 21575280 [TBL] [Abstract][Full Text] [Related]
18. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
19. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081 [TBL] [Abstract][Full Text] [Related]
20. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer. Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]